Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC

Phase 3 EVOKE-03/KEYNOTE-D46 reports numerically longer progression-free survival and higher response rates, but no statistically significant PFS or OS benefit

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

In the study, median progression-free survival (PFS) by blinded independent central review was 11.8 months with SG plus pembrolizumab compared with 7.7 months with pembrolizumab alone (HR, 0.81; 95% CI, 0.66-1.00; P=0.0252). Although PFS was numerically longer with the combination, the result did not meet the prespecified threshold for statistical significance. At the interim analysis, median overall survival was 21.5 months with SG plus pembrolizumab and 22.8 months with pembrolizumab alone (HR, 1.07; 95% CI, 0.85-1.35; P=0.7155).

"While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary PFS endpoint, and overall survival was not significantly improved at this interim analysis," said Giannis Mountzios, M.D., of the Henry Dunant Hospital Center, Athens, Greece. "These findings provide important information as we continue to evaluate treatment strategies for patients with PD-L1-high metastatic NSCLC."

EVOKE-03/KEYNOTE-D46 is an open-label Phase 3 study that enrolled 620 patients with previously untreated metastatic NSCLC, PD-L1 TPS of at least 50%, and no EGFR, ALK or ROS1 alterations. Participants were randomized to receive SG at 10 mg/kg intravenously on days 1 and 8 plus pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle, or pembrolizumab alone. The dual primary endpoints were PFS by blinded independent central review and overall survival.

The confirmed objective response rate was higher with SG plus pembrolizumab than with pembrolizumab alone. The abstract reports an objective response rate of 55.6% for the combination and 43.7% for pembrolizumab alone. The disease control rate reported in the study table was 83.3% versus 73.1%, respectively, and median duration of response was 21.4 months versus 21.3 months.

Treatment-related adverse events occurred in 93.2% of patients receiving SG plus pembrolizumab and 65.4% of those receiving pembrolizumab alone. Grade 3 or higher treatment-related adverse events occurred in 55.7% and 16.5% of patients, respectively. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea. The safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed with the combination.

Dr. Mountzios concluded that, despite a numerical improvement in PFS and a higher response rate, SG plus pembrolizumab did not meet statistical significance for PFS compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic NSCLC Overall survival also did not meet statistical significance at the interim analysis.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rackspace Technology, Inc. (NASDAQ: RXT) between May 7, 2026 and July 8, 2026 inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.

So what: If you purchased Rackspace securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Rackspace class action, go to https://rosenlegal.com/cases/rackspace-technology-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rackspace's enterprise AI efforts would require Rackspace to significantly re-prioritize its capacity and capital away from the profitable Private Cloud segment; (2) Rackspace's Public Cloud revenue was declining as customers contracted directly with hyperscale cloud platforms; (3) as a result, Rackspace was likely to significantly reduce a material portion of its Public Cloud infrastructure resale business; (4) as a result, Rackspace's fiscal year 2026 revenue would be significantly impacted; and (5) as a result of the foregoing, defendants' public statements about Rackspace's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Rackspace class action, go to https://rosenlegal.com/cases/rackspace-technology-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

Helen Woodward Animal Center's Surf Dog Surf-a-Thon was a first-of-its-kind event that transformed the irresistible sight of dogs on surfboards into a powerful force for good. What began as a celebration of canine courage and surf skills has grown into a beloved tradition that raises life-saving funds for orphan pets — while proving, year after year, that "man's best friend" is capable of truly phenomenal things. 

Hoping to earn a coveted spot among the "Top Surf Dogs," canine competitors will hit the waves in 10-minute heats, showing off their surfing skills before a panel of surf pros and passionate aficionados. Judges will score each furry competitor on ride length, wave technique, enthusiasm and, of course, confidence on the board. First-, second- and third-place winners will be crowned in each weight class, with the top dogs advancing to the ultimate showdown: the Best-In-Surf finals!  

The day will also unleash a separate Freestyle Surf Contest, where creativity takes center stage and almost anything goes on the waves. Two crowd-favorite categories are back: Duos & Trios, featuring two — and sometimes even three — dogs sharing a single surfboard, and the Peeps & Pups Tandem Competition, where four-legged surfers and their favorite humans team up to ride the waves together.

There's more in store for the whole family, with a full lineup of beachside activities and entertainment including a special ceremony honoring Surf Dog legends Sugar, Faith and Delilah, and the highly anticipated awards ceremony — where the day's top four-legged stars will take home their well-earned honors.  

What makes Helen Woodward Animal Center's Surf Dog Surf-a-Thon truly special is that every wave ridden helps create a second chance for an orphan pet. With all proceeds supporting Helen Woodward Animal Center's lifesaving work, the event gives surfing and fundraising pooches the chance to win prizes while making an incredible difference.

Portions of today's Surf Dog Surf-A-Thon competition (including the "Best in Surf" Heat at 12:00 PM PST) will be streamed live on https://www.facebook.com/surfdogsurfathon/.

For more information on Helen Woodward Animal Center's Surf Dog Surf-A-Thon, visit https://animalcenter.org/surf-dog-surf-a-thon/ or call 858-756-4117.

About Helen Woodward Animal Center

Helen Woodward Animal Center is a private, non-profit organization where "people help animals and animals help people." Founded in 1972 in Rancho Santa Fe, Calif., the Center provides services for more than 90,000 people and more than 10,000 animals annually through adoptions, educational and therapeutic programs both onsite and throughout the community. For more information, go to:  www.animalcenter.org.

SOURCE Helen Woodward Animal Center

Share this article

Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). The study evaluated the company's first-in-class next-generation immuno-oncology therapy, ivonescimab, versus pembrolizumab as first-line treatment for patients with PD-L1-positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC).

The findings were selected as a Late-Breaking Abstract (LBA) for oral presentation and included in the official WCLC press program.

On September 13, the WCLC official website published the Abstract data on overall survival (OS) from the HARMONi-2 study. On September 15, Professor Caicun Zhou, Principal Investigator of HARMONi-2, IASLC President, and Director of the Department of Oncology at Shanghai East Hospital, will deliver the formal oral presentation (Oral) at the conference, sharing the complete results of the HARMONi-2 study with the global industry.

As of the data cutoff on August 20, 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming spending function was used, with a one-sided alpha of 0.0141.

Results showed that, compared with pembrolizumab, first-line treatment with ivonescimab significantly prolonged OS in patients with PD-L1-positive advanced NSCLC. This finding met the prespecified statistical significance threshold and demonstrated clear clinical benefit. The overall survival benefit was generally consistent across prespecified subgroups, with particularly pronounced benefit observed in the PD-L1-high population.

1. Intention-to-Treat (ITT) Population: Median OS of 30.8 Months with Ivonescimab, 27% Reduction in Risk of Death

- In the ITT population, ivonescimab monotherapy significantly prolonged OS versus pembrolizumab, with median OS of 30.8 months versus 22.6 months (HR=0.73; 95% CI: 0.57–0.95; P=0.009), corresponding to a 27% reduction in the risk of death.

2. Overcoming Traditional Anti-VEGF Treatment Contraindications: No Significant Increase in Bleeding Risk Observed in High-Risk Squamous Patients

Squamous NSCLC patients accounted for 45.5% of the HARMONi-2 population, and non-squamous patients for 54.5%. Among squamous patients treated with ivonescimab, 72.2% had central tumors, 10.0% had tumor cavitation or necrosis, and 6.7% had tumors encasing major vessels.

These populations are traditionally considered contraindicated or high-risk for anti-VEGF therapies and have long lacked effective treatment options. However, no apparent increase in bleeding risk was observed with ivonescimab, and these patients showed favorable benefit.

3. Consistent OS Benefit with Ivonescimab Regardless of PD-L1 Expression Level, with Particularly Pronounced Benefit in the TPS ≥50% Population

- In the PD-L1 TPS ≥50% subgroup, OS HR=0.58 (95% CI: 0.38–0.89), corresponding to a 42% reduction in the risk of death.

- In the PD-L1 TPS 1–49% subgroup, OS HR=0.85 (95% CI: 0.61–1.18), corresponding to a 15% relative reduction in the risk of death.

4. Consistent OS Benefit with Ivonescimab Regardless of Histology (Squamous and Non-Squamous)

- In the squamous cell carcinoma subgroup, OS HR=0.65 (95% CI: 0.45–0.95), corresponding to a 35% reduction in the risk of death.

- In the non-squamous subgroup, OS HR=0.79 (95% CI: 0.55–1.14), corresponding to a 21% reduction in the risk of death.

5. Favorable Overall Safety Profile with No New Safety Signals; Safety Characteristics Generally Consistent Between Arms

In May 2024, a prespecified interim analysis of progression-free survival (PFS) assessed by the Independent Data Monitoring Committee (IDMC) confirmed that HARMONi-2 met its primary PFS endpoint with statistically significant and clinically meaningful results. Median PFS was 11.14 months with ivonescimab versus 5.82 months with pembrolizumab (HR=0.51, P0.0001). This indication was approved in China in 2025.

HARMONi-2 is the first randomized, double-blind, controlled Phase III clinical study to demonstrate statistically significant positive OS and PFS results versus pembrolizumab.

An international multicenter Phase III clinical study evaluating ivonescimab monotherapy versus pembrolizumab as first-line treatment for PD-L1-high NSCLC (HARMONi-7/AK112-3007) is currently progressing efficiently.

To date, ivonescimab has consistently achieved dual-positive OS and PFS results across multiple Phase III head-to-head trials against PD-1/L1 therapies and continues to expand into major solid tumors beyond lung cancer. The synergistic antitumor effects of ivonescimab's dual "immuno-oncology + anti-angiogenesis" mechanism continue to be validated in both clinical research and real-world settings. Ivonescimab has the potential to provide a more effective treatment option with a manageable safety profile for cancer patients worldwide and to drive continued progress in oncology care.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

Share this article

The Wellness Room is part of a broader initiative between RBC and Conscientia Health that includes a wellness curriculum focused on mental health awareness, resilience, and coping strategies; educational programming workshops; and expanded support pathways for students and families. 

"This is about creating a culture where wellness is foundational to student success," said Nicole Wall, RBC Student Assistance Counselor. "As RBC continues to expand opportunities and strengthen student support systems, we remain committed to exceeding the needs of the whole child academically, spiritually, and emotionally." 

"We didn't choose today's date, the timing found us," said Dr. Simbiat Adighije (Dr. Sim), Founder of Conscientia Health, who has led the partnership. "But it's a reminder of why this work matters. Too many young people carry real struggles quietly, and too many adults around them don't know until it's a crisis. This room is one answer to that: a place where a student can be seen and supported before things reach that point. We're proud to build that alongside Red Bank Catholic." 

The Wellness Room includes a private consultation space, a group and workshop area for peer support sessions, and a self-guided check-in tool connecting students directly with a clinician when needed. The initiative is part of RISE by Conscientia, a program extending Conscientia's integrated care model into school communities. 

About Red Bank Catholic High School 

Red Bank Catholic is a vibrant, beloved, Catholic co-educational institution with a storied history, an extraordinary spirit, and a record of achievement in the classroom and beyond. Our programs pursue excellence in faith, academics, cultural awareness, athletics, and personal wellness in a mission to fully engage the minds, hearts, and souls of students in our Roman Catholic community so that they can succeed in every aspect of their lives. 

About Conscientia Health 

Conscientia Health is a telehealth provider offering integrated psychiatry, therapy, and primary care, with a mission to make whole-person care accessible and coordinated. Conscientia operates over 20 physical locations across New Jersey, providing hybrid in-person and virtual care. 

Conscientia Health's R.I.S.E. Teen Mental Health Program supports adolescents ages 12 to 19 through personalized teen mental health services for emotional, behavioral, and mental health challenges. We help teenagers reclaim their inner strength, develop practical life skills, and build resilience through integrated behavioral health and primary care support.

SOURCE Conscientia Health; Red Bank Catholic High School

Share this article

BRICS countries rally to counter shocks of power politics, unilateralism: China Daily editorial

BEIJING, Sept. 12, 2026 /PRNewswire/ -- The following article was published today by China Daily.

The 18th BRICS Summit, which opened on Saturday in New Delhi, the capital of India, is an opportunity for the participating countries to build consensus on development through strategic communication, improve the quality of development through practical cooperation, resolve differences through dialogue and consultation, and address risks and challenges through solidarity and collaboration.

This year marks the 20th anniversary of BRICS cooperation. Over the past two decades, the BRICS cooperation mechanism has become the world's most influential platform for cooperation among emerging markets and developing countries.

In his speech at Session I of the summit, President Xi Jinping reviewed the development of BRICS cooperation over the past two decades, underscoring that it has been 20 years of self-reliance and self-strengthening, with the member countries standing together through thick and thin and engaging in fruitful cooperation.

This has helped safeguard the common interests of the Global South, provided the world with stability and positive momentum, and ushered the grouping into a new stage of high-quality development with greater BRICS cooperation.

BRICS has become a major force for advancing a multipolar world and greater democracy in international relations. The grouping's growing influence is reflected in its expansion to 11 member countries and 10 partner countries, and in its economic and demographic scale. BRICS countries now account for approximately 40 percent of global GDP at purchasing power parity and nearly half of the world's population.

With the countercurrents of unilateralism and power politics surging, multilateralism and the international order are coming under strain, and the deficits in peace, development, security and governance continue to widen. That should further inspire the BRICS countries to stand firmly on the right side of history, strive to be pioneers of the times, steer the international order toward greater justice and equity, and work together to build a community with a shared future for humanity.

To that end, Xi called on BRICS to be a pioneer in pursuing innovation-driven development, upholding peace and stability, facilitating mutual learning between civilizations, and reforming and improving global governance.

Putting those proposals into action will help BRICS countries firmly seize the initiative in shaping their future. This will enable them to uphold a vision of common, comprehensive, cooperative and sustainable security, and play a constructive role in resolving hot spot issues by addressing both symptoms and root causes. It will also help them promote a fairer and more equitable global governance system.

Xi also proposed an initiative to promote new industrialization through artificial intelligence among BRICS countries, and said that China is willing to work with all parties to deliver more outcomes in research, development and application, and deepen cooperation in industrial and supply chains.

Xi also advocated efforts to deepen cooperation in culture, tourism and education, strengthen youth exchanges and promote more frequent interactions and closer bonds among the peoples.

These all represent concrete actions in China's commitment to advancing BRICS development and playing an active role.

Urging the group to deepen mutual understanding through communication and dialogue, Xi said that the BRICS countries should remain sincere and candid with one another, seek common ground while respecting differences, and respect each other's core concerns.

Over an extraordinary two-decade journey, solidarity and cooperation have remained the driving force behind the BRICS cause, Xi stressed.

China will take over as the rotating chair of BRICS and host its 19th summit next year, and the Chinese side stands ready to work with all parties to build consensus, create a better future and embark on BRICS' third "golden decade", jointly opening up a bright future of prosperity and progress.

The leaders attending the summit reached a common understanding across a range of important areas, including security, cooperation and development, and adopted a joint declaration on Saturday. This demonstrates BRICS countries' clear-eyed assessment of the opportunities and challenges they face, as well as their shared willingness to build greater consensus on issues of common concern. This will help create favorable conditions for China, as the next rotating chair, to steer BRICS toward even greater development in the next stage.

SOURCE China Daily

Share this article

Hyundai Motor Group hosts "HMG Autonomous Driving Media Day", outlining its roadmap for the next era of autonomous driving; first showcase of Level 2++ technology

Dual-Track strategy accelerates Level 2+ production through NVIDIA collaboration while internalizing key autonomous driving technologies through proprietary Atria AI ...NVIDIA solutions-based Level 2+ production targeted for the H1 2028 and Level 2++ in H2 2028, followed by Atria AI-powered Level 2++ vehicles in H2 2029 ...Progressive sensor standardization across Hyundai Motor, Kia, 42dot and Motional brings together autonomous driving capabilities across the Group

Data Flywheel strategy establishes a virtuous cycle of data collection, training, validation and deployment to continuously advance AI capabilities ...Expands the Group's data ecosystem by leveraging its annual sales of 7 million vehicles and Data Union framework, while implementing a data-centric development framework based on hard example mining, continuous training and SER ...Real-world Level 4 pilot to launch in Gwangju by year-end in partnership with Korea's Ministry of Land, Infrastructure and Transport to secure large-scale validation data

42dot shares Vision-Language-Action (VLA)-based autonomous driving technology that integrates visual information and language-based reasoning to guide driving decisions ...VLA research focuses on addressing edge cases, while parallel development of end-to-end (E2E) autonomy and VLA models enhances technical stability and scalability ...VLA model validation currently underway, with on-road testing and the full development process scheduled to run through early next year

SEOUL, South Korea, Sept. 12, 2026 /PRNewswire/ -- Hyundai Motor Group (the Group) announced that it has put its Data Flywheel into full operation, marking a new phase in its autonomous driving technology strategy. The system creates a virtuous cycle of data collection, AI training, validation and deployment to secure a competitive advantage through accelerated learning and technology development.

During the Group's "HMG Autonomous Driving Media Day" at 42dot headquarters in Gyeonggi Province, Korea, the Group presented its autonomous driving development strategy, technology roadmap, key achievements and implementation plans. The presentation underscored the Group's strategic positioning in the global autonomous driving technology competition and detailed how integrated data and AI systems form the foundation for next-generation vehicle technology.

At the event, the Group identified the Data Flywheel as a key element of its autonomous driving competitiveness and shared the operational framework and execution strategy that transforms large-scale real-world driving data into continuous technology improvements.

42dot also introduced key technologies and the development progress for the Group's proprietary autonomous driving artificial intelligence, Atria AI, while outlining the background and future plans for its Vision-Language-Action (VLA) technology development initiative.

In line with the event, the Group unveiled footage of an Atria AI-equipped SDV Testbed navigating complex urban traffic without driver intervention. Operating at a Level 2++ capability, the autonomous driving system showcased in the footage illustrates how the Data Flywheel is enabling a continuous cycle of learning, validation and performance improvement. The footage is available on the Group's official YouTube channel.

"Autonomous driving competition is no longer about comparing specific features. Competitiveness is determined by how much data you secure, how quickly you learn and how effectively you can reflect those results in actual products and services. At its core, autonomous driving competitiveness comes down to having systems that enable continuous, rapid learning. Hyundai Motor Group will develop autonomous driving technology that customers can trust, based on a virtuous cycle of data, AI and validation. Our goal is to ensure the safety and quality levels customers can trust while we learn and improve rapidly." – Minwoo Park, President and Head of Advanced Vehicle Platform (AVP) Division at Hyundai Motor Group and CEO of 42dot

Share this article

Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators

Nomination Categories for Fast Company's Best Workplaces for Innovators in AI & Automation, Advertising, Marketing & PR

HOUSTON, Sept. 12, 2026 /PRNewswire/ -- Allstream Energy Partners has been nominated in multiple categories for Fast Company's Best Workplaces for Innovators program, recognizing organizations redefining their industries through innovation, leadership, and emerging technologies.

The company received nominations in six categories:

- Best Workplaces for Innovators North America

- AI, Automation and Machine Learning Excellence

- Advertising, Marketing and PR

- Small & Mighty Companies

- Innovative Leader of the Year: Efrain Garcia, Founder and CEO

- Innovative Team of the Year

The nominations recognize Allstream's investment in proprietary AI-driven marketing technologies, digital publishing solutions, and workflows designed to change how energy companies build visibility, authority, and customer engagement.

Where Oil and Gas Digital Marketing Meets Publishing

Allstream Energy Partners has developed an agency-plus-publisher model combining digital marketing, content creation, industry communications, media publishing, executive networking, and business development.

As artificial intelligence changes how buyers discover suppliers, manufacturers, engineering firms, service companies, and technology providers, Allstream helps clients position themselves to be recommended—not simply found.

Its integrated capabilities include AI marketing strategy, AI-optimized website development, SEO for Oil and Gas, Answer Engine Optimization, Generative Engine Optimization, AI search visibility, content marketing, industry publishing, public relations, social media, paid search, email marketing, event promotion, podcasting, branding, and digital advertising.

Innovation Built for Energy

Unlike a general marketing agency, Allstream was built specifically for oil and gas, energy, engineering, construction, manufacturing, and industrial markets. Each founder brings 27 years of experience supporting sales, business development, capital projects, technical services, industrial marketing, and digital strategy.

This experience gives Allstream an understanding of how technical buyers evaluate suppliers, how projects move through the market, and how engineering, procurement, operations, and executive teams consume information.

The company continues investing in proprietary methodologies that combine industry knowledge, journalism, publishing, AI optimization, communications, and business development strategy. As AI becomes an important starting point for supplier research and vendor discovery, Allstream helps organizations evolve beyond traditional SEO.

"Marketing has fundamentally changed," said Efrain Garcia, Founder and CEO of Allstream Energy Partners. "Our team recognized early that AI would transform how buyers discover companies, evaluate expertise, and make purchasing decisions. These nominations reflect our commitment to innovation and our mission to help the energy industry succeed in an AI-first world."

About Allstream Energy Partners

Allstream Energy Partners is a Houston-based, AI-powered marketing and media company serving the energy and industrial supply chain. Through SEO, GEO, AEO, AI-optimized websites, publishing, strategic communications, networking events, and business partnerships, Allstream helps Oil and Gas companies strengthen their brands, improve visibility across search engines and AI platforms, and generate qualified business opportunities.

Visit www.AllstreamEP.com

Media Contact:

Efrain Garcia

[email protected]

8324963004

Photo(s):

https://www.prlog.org/13170255

Press release distributed by PRLog

SOURCE Allstream Energy Partners

Share this article

Agog-Supported Works Win Two of Three Immersive Prizes at the 83rd Venice International Film Festival

Out of the Ashes receives the Venice Immersive Special Jury Prize and Empire at Sea receives the Venice Immersive Achievement Prize; the two projects offer distinct approaches to climate storytelling

LOS ANGELES, Sept. 12, 2026 /PRNewswire/ -- Two projects supported by Agog: The Immersive Media Institute won two of the three prizes awarded today in the Venice Immersive competition at the 83rd Venice International Film Festival. Out of the Ashes, co-directed by Rory Mitchell and Nonny de la Peña, received the Venice Immersive Special Jury Prize. Empire at Sea, created and directed by Peter Flaherty, earned the Venice Immersive Achievement Prize.

The awards celebrate two distinct approaches to climate storytelling. Out of the Ashes is a virtual-reality documentary about loss, memory, resilience, and rebuilding after the January 2025 Los Angeles fires. Empire at Sea is an interactive solarpunk augmented-reality drama that asks audiences to confront questions of sustainability, migration, inclusion, and collective survival.

"Wendy Schmidt and I founded Agog on the belief that immersive media can bring people closer to urgent issues and help them imagine what change could look like," said Chip Giller, co-founder and executive director of Agog. "At Venice, we saw creators expand what these emerging technologies can do—and audiences responded in deeply personal ways. Out of the Ashes brought people from around the world close to the human toll of the Los Angeles fires, and many saw echoes of what their own communities have experienced. Empire at Sea shows new possibilities for filmmaking by pairing cinematic performance and an accomplished cast with the power of immersive media. Seeing both works recognized on a global stage makes us more excited than ever about immersive media's potential to advance storytelling, contribute to social change, and serve the public good."

"Out of the Ashes and Empire at Sea are ambitious, deeply human works that demonstrate the creative range of immersive storytelling," said Liz Rosenthal and Michel Reilhac, curators of Venice Immersive. "Agog made a meaningful contribution to Venice Immersive this year, not only through its support of three projects selected for competition, but also by creating spaces where artists, producers, technologists, and changemakers could experiment, exchange ideas, and form new connections. That combination of supporting individual projects and investing in the wider ecosystem is exactly what an emerging field needs to grow."

About Out of the Ashes

Narrated by award-winning actor Courtney B. Vance, Out of the Ashes places audiences within the events and aftermath of the Los Angeles wildfires. The 26-minute documentary combines first-person storytelling with volumetric reconstructions of participants' homes, created in part from their own family photos and videos. It closes by highlighting community organizations leading recovery efforts, including My Tribe Rise, Evolve Altadena, and the Palisades Recovery Coalition.

The work was created by Rory Mitchell and Nonny de la Peña and co-produced by The Mercantile Agency, Emblematic Group, and Arizona State University's MA in Narrative and Emerging Media program, with support from Agog and the MacArthur Foundation.

Out of the Ashes assets: project page | press kit

About Empire at Sea

Empire at Sea is a 22-minute interactive augmented-reality drama about climate scientists building a sustainable community on a remote oil rig after a catastrophe cuts them off from the mainland. Up to 10 audience members experience cinematic holograms around a custom interactive LED table and navigate together a story about science, sustainability, immigration, and community.

The work was created, directed, and produced by Peter Flaherty; commissioned by Lincoln Center for the Performing Arts and ASU Gammage; developed with Flaherty Pictures, 4DV.ai, and NightLight Labs; and supported by Agog, the Schwarzman Center at Yale University, and the Alfred P. Sloan Foundation. It is scheduled to be presented at Lincoln Center in January 2027.

Empire at Sea assets: project page | website | press kit

Agog at Venice Immersive

Agog supported three projects selected for this year's Venice Immersive competition. The third, Solwata, is a mixed-reality documentary that brings audiences into the lives of communities in Solomon Islands confronting rising seas, displacement, and planned relocation. Created by NowHere Media and co-produced by Human Rights Watch and Agog, the experience is narrated and executive produced by Mark Ruffalo. Following its Venice premiere, Solwata is now being presented at the Toronto International Film Festival's Innovation Hub through Sept. 16. It will next appear at the BFI London Film Festival and COP31, the annual United Nations climate change conference.

Beyond its involvement with the three projects, Agog partnered with Venice Immersive on the occasion of the festival's 10th anniversary to shape discussions about what the next decade could hold, with a focus on impact. Throughout the festival, Agog convened creators, nonprofit leaders, funders, technologists, and cultural leaders for programming including a Smart Glasses Petting Zoo offering hands-on access to the latest emerging technology to consider ways it could be harnessed for storytelling and social good, an imagination workshop focused on expanding what is possible in immersive storytelling, and hands-on- conversations about new creative possibilities and the opportunities for immersive media to spur social change.

These activities are part of Agog's broader efforts to champion ambitious work, connect people across the immersive ecosystem, and help immersive media develop with public purpose at its center. Learn more

About Agog: The Immersive Media Institute

Agog: The Immersive Media Institute is a philanthropic organization founded by Chip Giller and Wendy Schmidt that is dedicated to helping creators and nonprofit leaders use immersive media—including virtual, augmented, and mixed reality—to imagine and build a more connected, just, and compassionate world. Agog operates as a field builder and creative partner, supporting immersive storytellers whose work addresses urgent social and environmental challenges. Learn more at agog.org

Media Contacts

Alex Capriotti

Agog

[email protected]

+1-559-349-2804

Jaqueline Lee Rivera

Bryson Gillette

[email protected]

+1-817-917-5741

SOURCE Agog: The Immersive Media Institute

Share this article

RADNOR, Pa., Sept. 12, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by D-Wave Quantum Inc. ("D-Wave") (NASDAQ: QBTS) on behalf of investors who purchased or acquired D-Wave securities and experienced significant financial losses.

D-Wave Reports Disappointing Financial Results

On August 6, 2026, D-Wave reported disappointing financial results for the second quarter of 2026 including, among other items, revenue of only $3.08 million, missing analyst expectations in the range of $4.03 million to $4.08 million. Then, on August 25, 2026, D-Wave issued a press release announcing the resignation of its CFO, effective September 2, 2026.

D-Wave's Stock Drops Over 9%

Following the August 6, 2026, news of D-Wave's poor financial results, the company's stock price fell over 9%, and fell again, over 9%, on August 26, 2026.

Investors who purchased D-Wave Quantum Inc. (NASDAQ: QBTS) securities and experienced losses may have legal rights under the federal securities laws.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:

If you purchased or acquired D-Wave Quantum Inc. securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/qbts-dwave-quantum-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=qbts&mktm=PR 

There is no cost or obligation to speak with an attorney.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

CONTACT:

Jonathan Naji, Esq.

280 King of Prussia Road

Radnor, PA 19087

(484) 270-1453

[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

Share this article